- Home
- GLNG vs PRAX Comparison
GLNG vs PRAX Comparison
Compare GLNG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLNG | PRAX |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLNG | PRAX |
|---|---|---|
| Price | $37.07 | $271.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $51.13 | ★ $349.79 |
| AVG Volume (30 Days) | ★ 1.1M | 822.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 333.77 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $326,627,000.00 | $7,463,000.00 |
| Revenue This Year | $50.18 | N/A |
| Revenue Next Year | $0.91 | $12,467.71 |
| P/E Ratio | $67.01 | ★ N/A |
| Revenue Growth | 19.15 | ★ 364.98 |
| 52 Week Low | $29.56 | $26.70 |
| 52 Week High | $45.98 | $286.50 |
Technical Indicators
Market Signals| Indicator | GLNG | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 65.80 |
| Support Level | $36.75 | $262.31 |
| Resistance Level | $38.39 | $286.50 |
| Average True Range (ATR) | 0.80 | 14.00 |
| MACD | 0.03 | -1.31 |
| Stochastic Oscillator | 21.96 | 57.15 |
Price Performance
Historical ComparisonAbout GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.